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Abstract
Background: Tolerogenic dendritic cells (tolDC) have been postulated as a potent immunoregulatory therapy for
autoimmune diseases such as multiple sclerosis (MS). In a previous study, we demonstrated that the administration
of antigen-specific vitamin D3 (vitD3) tolDC in mice showing clinical signs of experimental autoimmune
encephalomyelitis (EAE; the animal model of MS) resulted in abrogation of disease progression. With the purpose
to translate this beneficial therapy to the clinics, we have investigated the effectivity of vitD3-frozen antigen-specific
tolDC pulsed with myelin oligodendrocyte glycoprotein 40-55 peptide (f-tolDC-MOG) since it would reduce the
cost, functional variability and number of leukapheresis to perform to the patients.
Methods: Mice showing EAE clinical signs were treated with repetitive doses of f-tolDC-MOG. Tolerogenic
mechanisms induced by the therapy were analysed by flow cytometry and T cell proliferation assays.
Results: Treatment with f-tolDC-MOG was effective in ameliorating clinical signs of mice with EAE, inhibiting
antigen-specific reactivity and inducing Treg. In addition, the long-term treatment was well tolerated and leading to
a prolonged maintenance of tolerogenicity mediated by induction of Breg, reduction of NK cells and activation of
immunoregulatory NKT cells.
Conclusions: The outcomes of this study show that the use of antigen-specific f-tolDC promotes multiple and
potent tolerogenic mechanisms. Moreover, these cells can be kept frozen maintaining their tolerogenic properties,
which is a relevant step for their translation to the clinic. Altogether, vitD3 f-tolDC-MOG is a potential strategy to
arrest the autoimmune destruction in MS patients.
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Background
Multiple sclerosis (MS) is a complex chronic, inflamma-
tory and demyelinating disease affecting the central ner-
vous system (CNS) [1, 2]. Studies performed in patients
and animal models support that MS pathogenesis is medi-
ated by autoreactive T cells recognizing myelin peptides
[3, 4]. Different types of unspecific immunomodulatory or
immunosuppressive drugs, as well as monoclonal anti-
bodies, have been designed to block this autoimmune re-
action in MS patients. However, these therapies have a
limited effect in disease progression and numerous
adverse side effects.
In the last years, a new strategy has emerged in
order to restore self-tolerance in patients with auto-
immune disorders and transplantation. This approach
consists of personalized therapies using the patient’s
own cells manipulated or expanded to perform tolero-
genic (tolerogenic antigen-presenting cells (APC)) or
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regulatory functions (regulatory macrophages and T
cells, Mreg and Treg).
Dendritic cells (DCs) are professional APC able to in-
duce either immunity or tolerance. Different methodolo-
gies have been described to generate tolerogenic DCs
(tolDC) ex vivo from human peripheral blood mono-
cytes and murine bone marrow cells (pharmacological
treatment, cytokines and genetic engineering) [5]. All
these types of tolDC share different characteristics such
as semimature phenotype—low level of costimulatory
molecules and maturation-resistance— and poor stimu-
lation of alloproliferation and induce various tolerogenic
mechanisms: induction of T cell anergy, generation of
Treg and/or T cells deletion [6, 7].
Our group has been working on an autologous spe-
cific tolDC therapy for MS patients for many years. We
have developed a methodology to obtain myelin anti-
gens pulsed-tolDC from MS patients using vitamin D3
(vitD3) in good manufacture practice (GMP) condi-
tions [8]. With the purpose to evaluate the efficacy of
the treatment, we used the animal model of MS, the
experimental autoimmune encephalomyelitis (EAE).
The studies performed show that the treatment with
vitD3 tolDC-myelin oligodendrocyte glycoprotein
(MOG)40-55 peptide (tolDC-MOG) in mice showing
clinical signs of EAE was able to abrogate disease
progression. However, the beneficial effect of the
antigen-specific therapy was not stable and several ad-
ministrations of cells were required [9]. The repetitive
administration of tolDC implies a large number of
leukapheresis and tolDC batches production (one for
each administration) in GMP conditions, thus becom-
ing an expensive and poor feasible treatment for trans-
lation of the clinic. The use of cryopreserved tolDC
has been elucidated as a solution since one leukapher-
esis provides enough monocytes to produce large
number of tolDC, which can be cryopreserved in
ready-to-use aliquots. In this sense, Radhakrishnan and
co-workers reported that cryopreserved DC vaccines
retained in vitro and in vivo therapeutic efficacy to in-
hibit breast cancer growth in mice [10]. However, the
process to obtain tolDC is most difficult and may be
susceptible to the cryopreservation process. In this
sense, cryopreserved tolDC were administrated during
the clinical trial conducted by Giannoukakis in patients
with type I diabetes (T1D) [11]. Although the treat-
ment in patients was safe and well tolerated, to date,
the effectiveness of frozen-specific tolDC-restoring
self-tolerance has not been investigated in vivo. In the
present study, we analyse the clinical efficacy of frozen
vitD3 tolDC-MOG (f-tolDC-MOG) and the long-term
treatment with repetitive administrations of these cells
in mice with EAE. In addition, we also investigated
immunotolerogenic mechanisms related with the
clinical benefit following a long-term treatment with f-
tolDC-MOG.
Methods
Animals
Female C57BL/6J mice, 8–10 weeks old, were purchased
from Harlan Laboratories (Holand). The mice were housed
under standard light- and climate-controlled conditions,
with standard chow and water provided ad libitum.
All experiments were performed in strict accordance
with EU and governmental regulations (Generalitat de
Catalunya, Decret 214/97 30th July). The Ethics Committee
on Animal Experimentation of the “Germans Trias i Pujol”
Research Institute approved all procedures described in this
study (protocol number: 5315).
EAE induction and clinical follow-up
Mice were immunized subcutaneously with 100 μg of
MOG40-55 (YRSPFSRVVHLYRNGK) (Institut de Recerca
Biomèdica de Barcelona, IRBB, Barcelona, Spain) and
emulsified (1:1) in Freund’s complete adjuvant contain-
ing 4 mg/mL of Mycobacterium tuberculosis (strain
H37RA, Difco, Detroit, MI). In addition, mice were also
injected intravenously with 250 ng of pertussis toxin
(Sigma Chemical, St. Louis, MO, USA) at days 0 and 2.
All animals were weighed and examined daily for wel-
fare and clinical signs. Clinical evaluation was performed
in a blinded manner by two different observers accord-
ing to the following criteria: 0, asymptomatic; 0.5, lost of
distal half of tail tone; 1, lost of entire tail tone; 1.5, hind
limb weakness; 2, hind limb paralysis; 2.5, hind limb
paraplegia; 3, forelimb weakness; 4, quadriparesia; 4.5,
severe quadriparesis; 5, quadriplegia; and 6, death. End-
point criteria were established to minimize suffering and
ensure animal welfare.
Frozen bone marrow-derived dendritic cells
Bone marrow-derived DCs (BMDCs) were generated as
previously described by Mansilla et al. 2015 [9]. Briefly,
progenitor bone marrow cells were obtained from
C57BL/6 donor mice and were cultured in medium
containing 1000 IU/mL of granulocyte-macrophage
colony-stimulating factor (GM-CSF; Prospec, Rehovot,
Israel). TolDC were generated by adding 1 nM 1α,25-
dihydroxyvitamin D3 (Calcijex, Abbott Laboratories, IL,
USA) for 8 days. On day 7, 0.1 mg/mL lipopolysaccharide
(LPS; Sigma) was added to the culture medium of mature
DCs (mDC) and tolDC, except in the case of immature
DCs (iDC). After 22–24 h, DCs were pulsed with 10 μM
MOG40-55 (tolDC-MOG) for 18 h or cultured with only
medium (unpulsed tolDC). Finally, 10 × 106 tolDC or
tolDC-MOG were cryopreserved in a proportion 1:1 in
freezing medium containing FBS and 20 % (v/v) DMSO.
The freezing medium was added drop by drop to the cells
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in cryovials, then transferred to containers with 2-
isopropanol and maintained at −80 °C for 24–48 h. After-
wards, cells were transferred and stored in a liquid nitrogen
container until use (cell aliquots remained a minimum of
4 days and a maximum of 8 months in liquid nitrogen).
In vivo treatment with frozen tolerogenic DC
Unpulsed f-tolDC and f-tolDC-MOG were thawed in 37 °C
water bath and washed twice with PBS. Cell viability
and counting were calculated using Perfect-Count Mi-
crospheres (Cytognos SL), Annexin V-allophycocyanin
(APC) (Immunoltools, Friesoythe, Germany) and 7-
AAD (Becton Dickinson [BD] Pharmingen, San Diego,
CA, USA) staining. Each mouse received a total of
three doses of 106 viable f-tolDC-MOG or PBS (vehicle)
intravenously (iv) and spaced by a fixed period of 4 days
between administrations. For the long-term treatment
with frozen cells (f-tolDC-MOG, f-tolDC or PBS), the
three initial doses each 4 days were followed by admin-
istrations which was required by an increase in the
mean clinical score of the f-tolDC-MOG group.
Antigen-specific T cell reactivity
Mice treated with f-tolDC-MOG or PBS (sham) on days
15, 19 and 23 pi (n = 8 in each group) were euthanized
on day 30 pi. Splenocytes were cultured in a 96-well
plate at 2 × 105 cells/well in 200 μL of supplemented
RPMI containing 5 μM MOG40-55 and either 5 μM of
phorbol 12-myristate 13-acetate (PMA) plus ionomicyn
(both from Sigma, positive control) or culture medium
(negative control). After 48 h of culture 1 μCi/well of
[3H]-thymidine (PerkinElmer, Waltham, MA, USA) was
added to each well for the last 18 h of culture. The
stimulation index (SI) for each stimulus was calculated
as the mean counts per minute (cpm) of antigen-
stimulated cultures divided by the mean cpm of the non-
stimulated cultures.
Antigen-specific proliferative stimulation of BMDC
To determine the antigen-specific stimulatory capacity
of fresh and frozen iDC, mDC and tolDC pulsed with
MOG40-55, a total of 5 × 10
3 of viable DC were incubated
for 5 days in supplemented RPMI containing 5 μg
MOG40-55 and 10
5 splenocytes from MOG-immunized
C57BL/6 mice (ratio 1:20), adding 1 μCi/well of [3H]-
methylthymidine for the last 18 h.
Flow cytometry
Surface phenotype of fresh and frozen iDC, mDC and
tolDC and phenotype of DC after 24 h stimulation with
0.1 mg/mL of LPS were determined by cellular staining
with anti-CD40, CD86 and IAIE (all from BD Bio-
science) and analysed in a FACSCanto II and FACSDiva
software (BD).
Lymphocyte subpopulations from ex vivo splenocytes
were analysed following the manufacturer’s instructions.
Briefly, 0.5 × 106 splenocytes were stained with mAb to
study Treg (anti-CD3, CD4, CD25 and FoxP3 (all from BD
Pharmingen)), Breg (anti-CD19, CD5 and CD1 (Biolegend,
San Diego, CA, USA)), NK and NKT cells (anti-CD3, CD4,
NKp1.1, NKp46 and CD27 (Biolegend)).
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 5.01 for Windows (La Jolla, CA, USA). Parametric
and nonparametric tests were used depending on the nor-
mality distribution of the variables. To compare data from
two groups, Mann–Whitney U or t tests were applied.
When more than two groups were compared, non-
parametric one-way ANOVA (Kruskal-Wallis) followed by
Dunnett’s multiple comparisons tests were applied.
Fisher’s exact test was used to compare qualitative vari-
ables. Differences were considered statistically significant
when P < 0.05. Data were expressed as the mean ± stand-
ard deviation (SD) values unless otherwise stated.
Results
No alterations of phenotypical and functional
characteristics of f-tolDC-MOG
To investigate the applicability of cryopreserved tolDC-
MOG, cells were generated as previously described [9] and
frozen in medium containing 10 % DMSO. After 24–48 h,
f-tolDC-MOG were stored in liquid nitrogen until use.
Analysis of the expression of costimulatory molecules
CD40 and CD86, as well as the MCH class II molecule
IAIE, revealed that f-tolDC-MOG phenotype remained
stable (similar level of expression of CD40, CD86 and
IAIE in fresh and frozen tolDC) (Fig. 1a). In addition, f-
tolDC-MOG showed a similar capacity to reduce antigen-
specific T cell reactivity to fresh tolDC-MOG (Fig. 1b).
Stability of f-tolDC-MOG was assessed after the
addition of a powerful inflammatory stimulus (LPS) for
24 h. In contrast to fresh or frozen iDC re-stimulated
with LPS—which exhibited an increased expression of
costimulatory molecules (mainly CD40) due to their
maturation—both, fresh and f-tolDC-MOG showed a
stable phenotype (Fig. 2).
The treatment with cryopreserved tolDC-MOG ameliorates
EAE
To analyse the in vivo effect of f-tolDC-MOG, a total of
1 × 106 viable f-tolDC-MOG or 200 μl PBS (vehicle)
were administrated intravenously (iv) to mice showing
clinical signs of EAE (on days +15, +19 and +23 pi). The
treatment with f-tolDC-MOG impeded disease progres-
sion and, therefore, animals receiving f-tolDC-MOG
showed an ameliorated clinical course of the disease
compared to animals treated with PBS, control group
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(f-tolDC-MOG = 2.39 ± 0.10, PBS = 3.91 ± 0.42; p <
0.0001) (Fig. 3a). In accordance, maximum and cumu-
lative scores of the group treated with f-tolDC-MOG
were reduced when compared to the control group
(Table 1). To determine the clinical efficacy of f-tolDC-
MOG treatment to improve EAE, non-responder (NR)
criteria was set up. Mice showing a ≥1 point increment in
the mean clinical score compared to their respective initial
clinical score (day +15 pi) were considered as NR. For
that, the mean clinical score during the period of treat-
ment duration (day +16 pi to +30 pi) was calculated for
each mouse. Just only one mouse from the total of eight
mice receiving f-tolDC showed a NR behaviour (12.5 %
NR), indicating the relevant beneficial clinical effect of f-
tolDC-MOG (p = 0.041) compared with the control group
(75 % NR) (Fig. 3b, c).
Increment of f-tolDC-MOG therapeutic effect during a
repetitive and long-term administration
When f-tolDC-MOG treatment efficacy in EAE was
demonstrated, a prolonged treatment with f-tolDC-
MOG, unpulsed f-tolDC or PBS was performed to deter-
mine the long-term efficacy and tolerability of the treat-
ment. As is shown in Fig. 4a and Table 1, the treatment
with f-tolDC-MOG until day +74 pi retained a pro-
longed clinical beneficial effect compared to vehicle or
tolDC group (f-tolDC-MOG = 2.35 ± 0.44, PBS = 3.51 ±
0.71, f-tolDC = 3.12 ± 0.37; p < 0.0001 in both compari-
sons). The repetitive and long-term administration of
unpulsed f-tolDC also exhibited a slighter amelioration
of EAE clinical signs compared to PBS-treated EAE mice
(p < 0.0001) (Fig. 4a and Table 1). However, following
the NR criteria, 9 out of 14 mice receiving unpulsed f-
tolDC did not show clinical improvement (64.3 % NR),
meanwhile only 4 out of 15 mice treated with f-tolDC-
MOG were NR (26.67 % NR) (Fig. 4b, c). As a result,
compared to the control group (Fig. 4d), only mice
receiving f-tolDC-MOG showed a significant clinical
responding behaviour (f-tolDC p = 0.895; f-tolDC-MOG
p = 0.003).
Finally, it was observed that long-term treatment with
unpulsed f-tolDC and f-tolDC-MOG were well tolerated
and, interestingly, periods of clinical stability were pro-
gressively longer after each administration, extending
the required interval dosing: first three administrations
each 4 days; three administrations each 9 days, and fi-
nally, one administration after 18 days (Fig. 4a).
Frozen tolDC-MOG treatment reduces antigen-specific
response
To characterize the response induced by f-tolDC-MOG,
splenocytes from mice sacrificed at day 30 pi were ob-
tained. Compared to vehicle-treated mice, splenocytes
from mice treated with f-tolDC-MOG showed an
increased percentage of Treg (CD3+ CD4+ CD25+
FoxP3+ cells 14.80 ± 2.30 vs. 9.48 ± 3.05, p = 0.017) and
a reduced MOG-proliferative response (1.19 ± 0.35 vs.
4.54 ± 1.59, p = 0.004) (Fig. 5a, b).
The maintenance of tolerogenicity is induced by a
reduction of NK cells alongside increment of Breg and
immunoregulatory NKT cell potential
In addition, further immune cell populations were ana-
lysed in mice having a long-term treatment (2 months)
with f-tolDC-MOG, f-tolDC or PBS. The results re-
vealed an increased number of Breg (CD19+ CD1dhigh
CD5+ cells) in mice treated with both f-tolDC-MOG
and unpulsed f-tolDC compared to the vehicle group
(313.8 ± 153.0 and 230.3 ± 108.9 vs. 142.4 ± 106.9; p =
0.039 and p = 0.019, respectively) (Fig. 6). When NK cells
were examined (NKp1.1+ NKp46+ CD3− cells), a reduc-
tion in the number of NK cells was observed in f-tolDC-
MOG and f-tolDC-treated mice, although differences
with the control group were only significant in the group
receiving antigen-specific cells (f-tolDC-MOG) (p =
Fig. 1 Phenotypical and functional stability of frozen tolDC-MOG.
Expression of CD40, CD86 and MHCII molecule IAIE was assessed
on fresh tolDC and f-tolDC-MOG. Data are expressed as mean
fluorescence intensity (MFI) (a). Antigen-specific proliferation of
MOG-reactive splenocytes co-cultured with fresh or frozen iDC-MOG,
mDC-MOG or tolDC-MOG. Data are expressed as counts per minute
(cpm) (b). Data from three independent experiments. Error bars
correspond to SEM
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0.132 and p = 0.031, respectively) (Fig. 7a). In the same
way, the expression level of NKp46 activation marker
was also reduced only in f-tolDC-MOG (f-tolDC-MOG
9677 ± 1184, f-tolDC 11,003 ± 1820 and PBS 11,218 ±
1232; p = 0.015 and p = 0.286, respectively) (Fig. 7b). Fur-
thermore, the expression of CD27 was also analysed in
the NK cell population. The tolerogenic therapy with
unpulsed f-tolDC and f-tolDC-MOG reduced the num-
ber of NK CD27- and NK CD27 low cells (reaching the
statistical significance only in f-tolDC-MOG-treated
mice), in contrast, only mice receiving f-tolDC-MOG
showed a reduction in number of NK CD27high cells
(p = 0.045) (Table 2).
Finally, the analysis of NKT cells (NKp1.1+ NKp46+
CD3− cells) revealed no differences in the number of
these cells in any treatment group (Fig. 7c). However,
an increase in the expression of NKp46 in NKT cells
from mice receiving a tolerogenic therapy (f-tolDC and
f-tolDC-MOG) was found in comparison with the mice
treated with PBS (f-tolDC-MOG 4311 ± 392.9, f-tolDC
4193 ± 573.0 and PBS 3649 ± 179.2; p = 0.003 and p =
0.010, respectively) (Fig. 7d).
Discussion
The encouraging results obtained from different in vitro
and pre-clinical studies in animal models have revealed
tolDC as a promising therapy for autoimmune diseases
and transplantation [5, 12, 13]. Consequently, some clin-
ical trials using tolDC have been initiated. The first
phase I clinical trial was carried on by Giannoukakis et
al. in T1D patients treated with autologous tolDC gener-
ated using antisense oligonucleotides against costimula-
tory molecules. The study reported that tolDC treatment
was safe and well tolerated, opening a new way to
treat autoimmune diseases without the side effects
related to immunosuppressive drugs [11]. In the
same way, other clinical trials have been recently re-
ported in other autoimmune diseases [14–16] (reviewed
in [17]). However, the production of tolDC in GMP con-
ditions is expensive and some critical points need to be
Fig. 2 Cryopreserved tolDC-MOG are phenotypically stable following stimulation with LPS. Expression of CD40 (a, b), CD86 (c, d) and MHCII molecule IAIE
(e, f) on fresh and frozen iDC-MOG, mDC-MOG and tolDC-MOG, after 24 h re-stimulation with LPS. Data are expressed as mean fluorescence intensity
(MFI). Data correspond to three independent experiments. Error bars correspond to SEM
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solved in order to bring tolDC therapy from the bench
to the bedside. The use of cryopreserved tolDC may be a
most feasible strategy, because it allows producing only
one batch of tolDC for all the required administrations
during the treatment. Therefore, the use of f-tolDC would
avoid submitting the patient to one leukapheresis process
for each cell injection, thus, reducing the production cost
and variability between tolDC batches. In contrast to
immunogenic DC, in which their function is retained after
cryopreservation [10], the in vivo beneficial effect of fro-
zen tolDC has not been demonstrated so far.
In the present work, we have demonstrated that vitD3
f-tolDC-MOG not only show in vitro phenotypical and
functional stability but also are able to abrogate EAE dis-
ease progression in vivo with clinical signs of EAE.
Furthermore, the results obtained by injecting vitD3 f-
Fig. 3 Cryopreserved tolDC-MOG treatment suppresses EAE progression. Clinical follow-up of mice treated with 1 × 106 viable frozen tolDC-MOG (f-tolDC-
MOG, n= 8) or PBS (vehicle, n= 8) on days +15 pi, +19 pi and +23 pi (a). Arrows indicate days of treatment administration. Error bars correspond to SEM.
Representation of individual clinical score of the initial day of treatment (day 15 pi) and the corresponding mean clinical score during the treatment period
(from 16 pi to 30 pi) from mice treated with f-tolDC-MOG (n= 8) (b) or PBS (vehicle, n= 8) (c). The mean clinical score during the treatment for each mouse
was calculated as the sum of daily scores from day 16 pi to 30 pi divided by 15 (number of follow-up days after treatment)
Table 1 Clinical data of experimental autoimmune encephalomyelitis (EAE) mice treated with frozen tolDC-MOG (f-tolDC-MOG) and
f-tolDC
30-day follow-up 74-day follow-up
Vehicle f-tolDC-MOG Vehicle f-tolDC f-tolDC-MOG
Maximum score 4.25 ± 0.96 2.69 ± 2.03 4.27 ± 1.21 4.14 ± 1.22 3.13 ± 1.79
Cumulative scorea 60.75 ± 17.92 38.00 ± 30.67 211.1 ± 83.19 188.4 ± 66.86 159.3 ± 96.58
aMean of the sum of daily scores for each mouse. Data are expressed as mean ± SD
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tolDC-MOG were comparable to our previously pub-
lished study treating EAE mice with fresh vitD3
tolDC-MOG, using the same administration schedule
[9]. Together with the suppression of antigen-specific
reaction and the increase of Treg response observed,
results indicate that frozen and fresh tolDC-MOG
exert the same beneficial mechanisms in mice with
clinical signs of EAE.
Fig. 4 Treatment with frozen tolDC-MOG (f-tolDC-MOG) shows a long-term beneficial effect. Clinical follow-up of mice treated with 1 × 106 viable
f-tolDC-MOG (n = 15), unpulsed f-tolDC (n = 14) or PBS (vehicle, n = 15) on days +14 pi, +18 pi, +22 pi, +31 pi, +40 pi, +49 pi and +67 pi. Arrows
indicate days of treatment administration (a). Error bars correspond to SEM. Representation of individual clinical score of the initial day of treatment
(day 14 pi) and the corresponding mean clinical score during the treatment period (from 15 pi to 74 pi) from mice treated with f-tolDC-MOG (n = 15)
(b), f-tolDC (n = 14) (c) or PBS (vehicle, n = 15) (d). The mean clinical score during the treatment for each mouse was calculated as the sum of daily
scores from day 15 pi to 74 pi divided by 60 (number of follow-up days after treatment)
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Once the tolDC-MOG production was optimized
using frozen cells, the next step was to analyse the effect
of a long-term treatment with such cells and get further
information for the translationality of this therapy to MS
patients. For this purpose, an experiment of 74 days
follow-up was performed. The three initial administra-
tions were performed in a short period (every 4 days 14,
18 and 22 pi) as a shot to stop disease progression, while
the next administrations were performed only when a
worsening in the f-tolDC-MOG-treated group was de-
tected. Interestingly, we observed that after several
administrations of f-tolDC-MOG, periods of clinical sta-
bility were progressively longer, thus indicating that a
more stable or prolonged tolerogenic effect was achieved
after repetitive administrations of f-tolDC-MOG.
To determine the clinical effectiveness of the treat-
ment with f-tolDC-MOG, classification of NR mice was
established as mice showing an increment of ≥1 point in
the mean clinical score during the treatment period
(from 15 pi to 74 pi), compared to their respective score
of the first day of treatment (14 pi). As shown, the
antigen-specific therapy demonstrated to be the most
tolerogenic treatment, being effective in 73.33 % of mice
compared to the 35.7 % of the group of mice receiving
unpulsed f-tolDC. In vitro studies performed with sple-
nocytes confirmed that the beneficial effect of f-tolDC-
MOG was related to an abrogation of antigen-specific
response and Treg response induction, as previously de-
scribed with fresh tolDC-MOG treatment [9].
Finally, the repetitive and long-term treatment with f-
tolDC-MOG resulted in an intriguing prolonged clinical
amelioration after each administration, suggesting that dif-
ferent tolerogenic mechanisms were elicited with the pass-
ing of time by this antigen-specific therapy. To investigate
the mechanisms related with the maintenance of periph-
eral tolerogenicity, Treg (data not shown), Breg, NK and
NKT cells immunoregulatory populations were analysed.
One of the most relevant tolerogenic mechanisms in-
duced by tolDC therapies in addition to Treg are Breg
(most B10 or IL-10 producers) since they have demon-
strated immunoregulatory functions in EAE, inflammatory
bowel disease and collagen-induced arthritis [18, 19]. The
most relevant result from the phase I clinical trial in T1D
Fig. 5 Reduced antigen-specific reactivity and increased percentage of regulatory T cells (Treg) of splenocytes from mice treated with frozen
tolDC-MOG (f-tolDC-MOG). Percentage of CD25 + FoxP3+ cells (Treg) in ex vivo splenocytes of f-tolDC-MOG and PBS-treated mice (n = 5 and n = 6,
respectively) (a). MOG-induced proliferative response from mice treated with f-tolDC-MOG (n = 5) or PBS (vehicle, n = 6). The data are expressed as
stimulation index (SI). The error bars correspond to SEM. *p < 0.05, **p < 0.01 (b)
Fig. 6 Treatment with tolDC increases regulatory B cells (Breg) in
mice with EAE. Number of CD19+ CD1hi CD5+ cells (Breg) in ex
vivo splenocytes of f-tolDC-MOG, f-tolDC and PBS-treated mice (n =
8, n = 12 and n = 11, respectively). The error bars correspond to SEM.
*p < 0.05, **p < 0.01
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was the increase frequency of immunosuppressive B cells
[11, 20]. The ex vivo analysis of splenocytes from f-tolDC-
MOG or f-tolDC-treated mice did not reveal differences
in the number of Treg (data not shown). However, in-
creased number of CD19+ CD1hi CD5+ cells (Breg) com-
pared to the control group was found. Nevertheless, this
regulatory mechanism was less potent in mice receiving f-
tolDC than those receiving the antigen-specific therapy (f-
tolDC-MOG).
A crucial role of NKT cells in anti-microbial and anti-
cancer response, as well as preventing autoimmune diseases
such as MS, T1D, lupus or RA, has been reported [21, 22].
NKT cells constitute a minority population of T cells that
express NK receptors (i.e. NK1.1) and recognize glycolipids
by semi-invariant CD1d-restricted αβ T-cell receptors
(TCR). Therefore, they are in the interface between innate
and adaptive immunity, showing important immunoregula-
tory properties [21]. The NKT-DC interactions can elicit
either IFN-γ secretion and subsequent DC maturation, or
IL-4 release, promoting tolDC differentiation [22]. In
addition, reduced number of NKT cells in patients and ani-
mal models of autoimmune disorders (including MS and
EAE) has been reported [23]. Notwithstanding, the regula-
tory potential of NKT is still on debate because CD1d or
Jα18 knock-out C57Bl/6 mice did not develop spontaneous
EAE, different strategies inducing or increasing NKT cells
have ameliorated the disease symptoms.
The analysis of NKT population in EAE mice receiving
tolDC-MOG, tolDC or PBS did not show differences in
the number of NKT cells between groups. However,
higher expression of the activation NK cell marker,
NKp46, was found in mice treated with tolDC-MOG. Al-
though additional studies must be performed, results
could indicate that the repetitive and long-term treatment
with tolDC-MOG increases NKT cells regulatory func-
tions and contribute to prolong/maintain the clinical
benefit in mice receiving the antigen-specific treatment.
Interestingly, a remarkable reduction in the number of
NK cells was found in f-tolDC-MOG-treated mice com-
pared to the control group. NK cell function is regulated
by a balance of positive and negative signals. To investi-
gate the activation status of NK cells from spleen cells of
different mice, the expression of the receptors NKp46
and CD27 was determined. The results suggest that be-
sides of NK cells reduction, the tolerogenic therapy with
Fig. 7 Effect of treatment with tolDC on NK and NKT cell subpopulations. Number of NK cells (NKp1.1+ NKp46+ CD3−) (a) and median fluorescence
intensity (MFI) of the NKp46 activation marker (b) in ex vivo splenocytes from f-tolDC-MOG, unpulsed f-tolDC and PBS-treated mice (n = 6, n = 11 and
n = 10, respectively). Number of NKT cells (NKp1.1+ NKp46+ CD3+) (c) and NKp46 MFI (d) of splenocytes from f-tolDC-MOG, unpulsed f-tolDC and PBS-
treated mice (n = 6, n = 11 and n = 10, respectively). The error bars correspond to SEM. *p < 0.05
Table 2 Analysis of NK cells in mice receiving tolerogenic
therapy
NK CD27− NK CD27low NK CD27hi
f-tolDC-MOG 177.5 ± 42.1* 66.67 ± 19.3* 255.7 ± 74.7*
f-tolDC 176.7 ± 108.1* 87.09 ± 33.3 384.9 ± 144.7
Vehicle 295.9 ± 126.0 123.0 ± 42.8 391.9 ± 147.8
Data are expressed as mean ± SD
*p < 0.05
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f-tolDC and f-tolDC-MOG decreased NK cell activation
(measured by less NKp46 expression and reduced
CD27low NK cells) compared to the PBS group. None-
theless, the most potent effect was achieved exclusively
by the antigen-specific therapy, probably due to the sig-
nificant reduction of cytotoxic NK cells (CD27high),
which have lower activation threshold than CD27low
NK cells [24, 25].
Taken together, these results show that the treatment
of mice showing EAE clinical signs with vitD3 f-tolDC-
MOG was able to abrogate the disease mediated by an
inhibition of antigen-specific reactivity, increment of
Treg, Breg and activated NKT cells and reduction of NK
cells. The long term-treatment with f-tolDC-MOG was
well tolerated, highly effective and exhibited a prolonged
clinical benefit after each administration.
Conclusions
We have demonstrated that vitD3-frozen tolDC-MOG is
a feasible cell-based therapy, with a potent immunoregu-
latory function in EAE and, potentially, in MS patients.
The results emphasize the relevance to perform antigen-
specific treatment. Therefore, efforts must be focus on
identifying autoantigen peptide candidates to be loaded
in tolDC according to the target autoimmune disease.
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